- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 223
Inipharm harvests $35m in series A round
The round included Jubilant Biosys, an existing investor in the liver disease drug startup as well as its contract research organisation partner.
Nov 13, 2020Wellness Forever takes care with fresh funding
Allana Group has returned to back a $17.6m round for the dispensary chain owner, five years after its contribution to a $3.2m round for the company.
Nov 13, 2020Daily deal net: November 12, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Nov 12, 2020Neuros Medical brainstorms $37m
Neuros Medical, a Case Western Reserve University spinout, has raised $69.8m since it was founded in 2008.
Nov 12, 2020Silverback goes for IPO gold
The cancer immunothrapy developer has filed to raise up to $100m in an offering that will follow $211m from backers including Celgene and Bristol-Myers Squibb.
Nov 12, 2020Neuros Medical brainstorms $37m
Boston Scientific-backed pain relief implant developer Neuros has now raised about $70m in total and is targeting $42.8m in its latest round.
Nov 12, 2020Adagio Therapeutics adds $80m
Adagio has raised money in a GV-led series B round that will support the entry of its covid-19 drug candidate into clinical trials early next year.
Nov 12, 2020Synendos synthesises $26.4m series A
Ysios Capital has supplied a series A extension that follows an initial tranche co-led by Kurma Partners and Sunstone Life Science Ventures in November 2020.
Nov 12, 2020Catalym catalyses $59m
Julius-Maximilians-University of Würzburg's cancer immunotherapy developer Catalym plans to move its lead asset into the clinic next month.
Nov 11, 2020RecBio receives $227m in series B round
Legend Capital was among the participants as Rec-Biotechnology raised series B funding that will be used for clinical trials of its vaccine candidates.
Nov 11, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


